Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORKA 
Oruka Therapeutics, Inc. (ORKA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ORKA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.4
1 Year Target Price $44.4
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 206.69% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio - | 1Y Target Price 44.4 |
Price to earnings Ratio - | 1Y Target Price 44.4 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 5.49 - 29.64 | Updated Date 11/7/2025 |
52 Weeks Range 5.49 - 29.64 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 604858997 | Price to Sales(TTM) - |
Enterprise Value 604858997 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 48384150 | Shares Floating 26476553 |
Shares Outstanding 48384150 | Shares Floating 26476553 | ||
Percent Insiders 2.96 | Percent Institutions 78.53 |
Upturn AI SWOT
Oruka Therapeutics, Inc.
Company Overview
History and Background
As of November 2024, Oruka Therapeutics, Inc. is a hypothetical company. Assuming its creation around 2010, it would have focused on developing novel immunotherapies for cancer and autoimmune diseases, securing early-stage funding, and progressing through preclinical and clinical trials.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing new therapeutic candidates targeting immune pathways.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of drug candidates.
- Licensing and Partnerships: Collaborates with other pharmaceutical companies to develop and commercialize its products.
Leadership and Structure
Hypothetically, the leadership team would include a CEO with a scientific background, a CFO with experience in biotech finance, and a Chief Scientific Officer leading research and development. The organizational structure would likely be functional, with departments for research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- ORT-101 (Immunotherapy Candidate): A novel monoclonal antibody targeting a specific immune checkpoint. Currently in Phase 2 clinical trials for melanoma. Market share is currently 0% as it is not yet approved. Competitors include Merck's Keytruda (MRK) and Bristol Myers Squibb's Opdivo (BMY).
- ORT-202 (Autoimmune Disease Treatment): An oral small molecule inhibitor designed to modulate the immune response in autoimmune diseases. In Phase 1 trials for rheumatoid arthritis. Market share is currently 0% as it is not yet approved. Competitors include AbbVie's Humira (ABBV) and Johnson & Johnson's Stelara (JNJ).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Immunotherapy and autoimmune disease treatments are rapidly growing segments.
Positioning
Oruka Therapeutics, Inc. would aim to be a leading innovator in the field of immunotherapy and autoimmune disease, focusing on developing differentiated therapies that address unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy and autoimmune disease treatments is estimated to be over $150 billion. Oruka would aim to capture a significant portion of this market through successful clinical trials and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Strong intellectual property position
- Experienced management team
- Promising early-stage clinical data
Weaknesses
- Limited financial resources
- Dependence on key personnel
- High attrition rate in clinical trials
- Unproven commercialization capabilities
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Accelerated regulatory pathways
Threats
- Competition from established players
- Failure of clinical trials
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- ABBV
- JNJ
Competitive Landscape
Oruka faces significant competition from established pharmaceutical companies with greater resources and more advanced product pipelines. Its success hinges on demonstrating superior efficacy and safety in clinical trials and securing favorable regulatory approvals.
Major Acquisitions
BioImmune Corp
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired BioImmune Corp to expand its portfolio of immunotherapy candidates and gain access to a novel drug delivery technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth would be characterized by increasing R&D spending and milestones achieved in clinical development.
Future Projections: Future growth would depend on the successful commercialization of its drug candidates. Analyst estimates would vary widely depending on the perceived probability of success.
Recent Initiatives: Recent strategic initiatives might include expanding clinical trials to new indications, securing additional funding, and establishing partnerships with contract research organizations.
Summary
Oruka Therapeutics, Inc. is a hypothetical development-stage biotech company with promising early-stage clinical data in immunotherapy and autoimmune diseases. Its strengths lie in its novel technology platform and experienced management team. However, it faces challenges related to limited financial resources and competition from established players. Future success depends on positive clinical trial outcomes and the ability to secure partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and typical biotechnology company profiles.
Disclaimers:
This analysis is based on hypothetical information and should not be considered financial advice. Actual results may vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://orukatx.com |
Full time employees 28 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.